Drug Type Antibody fusion proteins |
Synonyms Anti-PD-1-IL-18 antibody |
Target |
Action agonists, inhibitors |
Mechanism IL18R1 agonists(Interleukin 18 receptor agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 22 Mar 2024 |